Bruker (BRKR) Stock Could Be 27% Below Fair Value After Shelf Filing

Simply Wall St.06-23

AdvertisementWhat Bruker’s New Shelf Registration Means For Investors Bruker (BRKR) has filed an omnibus universal shelf registration that covers common and preferred stock, debt securities, warrants,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2645400269?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000","is_english":true,"pubTime":"2026-06-23 10:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2645400269","market":"nz","top_or_hot":-1,"title":"Bruker (BRKR) Stock Could Be 27% Below Fair Value After Shelf Filing","media":"Simply Wall St.","content":"<div>\n<p>AdvertisementWhat Bruker’s New Shelf Registration Means For Investors Bruker (BRKR) has filed an omnibus universal shelf registration that covers common and preferred stock, debt securities, warrants,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-could-be-27-below-fair-value-after-shelf-f\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bruker (BRKR) Stock Could Be 27% Below Fair Value After Shelf Filing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBruker (BRKR) Stock Could Be 27% Below Fair Value After Shelf Filing\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-23 10:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-could-be-27-below-fair-value-after-shelf-f><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AdvertisementWhat Bruker’s New Shelf Registration Means For Investors Bruker (BRKR) has filed an omnibus universal shelf registration that covers common and preferred stock, debt securities, warrants,...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-could-be-27-below-fair-value-after-shelf-f\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1815336091.USD","symbol_name":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-could-be-27-below-fair-value-after-shelf-f","article_id":"2645400269","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/9551728-choice1-main-header/1585186657000"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-brkr/bruker/news/bruker-brkr-stock-could-be-27-below-fair-value-after-shelf-f","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2645400269","pubTimestamp":1782181483,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"What Bruker’s New Shelf Registration Means For Investors\nBruker (BRKR) has filed an omnibus universal shelf registration that covers common and preferred stock, debt securities, warrants, units, depositary shares, subscription rights, and purchase contracts, giving the company broad flexibility to raise capital.\nSee our latest analysis for Bruker.\nBruker’s shelf registration lands at a time when the stock has seen strong recent momentum, with a 30 day share price return of 23.73% and a 90 day...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1815336091.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AUP\" (USD) INC","BRKR":"布鲁克","LU0757428866.USD":"THREADNEEDLE (LUX) GLOBAL SMALLER COMPANIES \"AE\" (USD) ACC","BK4121":"生命科学工具和服务"},"translate_title":"搁置备案后，布鲁克(BRKR)股票可能比公允价值低27%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BRKR":1.5},"content_text":"AdvertisementWhat Bruker’s New Shelf Registration Means For Investors Bruker (BRKR) has filed an omnibus universal shelf registration that covers common and preferred stock, debt securities, warrants, units, depositary shares, subscription rights, and purchase contracts, giving the company broad flexibility to raise capital. See our latest analysis for Bruker. Bruker’s shelf registration lands at a time when the stock has seen strong recent momentum, with a 30 day share price return of 23.73% and a 90 day share price return of 57.86%. However, a 3 year total shareholder return that is still down 21.95% suggests longer term holders have had a more mixed experience. If you want to see what else is moving around recent capital raising stories, it can be useful to scan 20 top founder-led companies With Bruker trading at $56.53, a discount of 27% to one intrinsic value estimate but above an average analyst target of $53.25, you have to ask: is there still upside here, or is future growth already priced in? Most Popular Narrative: 6% Overvalued The most followed narrative currently anchors Bruker’s fair value at $53.25, a little below the recent $56.53 close, and builds a detailed case around earnings and margins.  The analysts have a consensus price target of $53.25 for Bruker based on their expectations of its future earnings growth, profit margins and other risk factors. In order for you to agree with the analysts, you would need to believe that by 2029, revenues will be $4.0 billion, earnings will come to $328.4 million, and it would be trading on a PE ratio of 31.5x, assuming you use a discount rate of 8.2%.  Read the complete narrative. Want to see what sits behind those revenue, earnings and margin assumptions for Bruker, and how they add up to that projected valuation multiple and fair value narrative? Result: Fair Value of $53.25 (OVERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the Bruker narrative still faces clear risks, including pressure on academic and biopharma funding and higher helium costs that could squeeze margins and temper sentiment. Find out about the key risks to this Bruker narrative. Another View: Bruker On Sales Based Valuation While the most followed Bruker narrative focuses on earnings forecasts and a fair value of $53.25, the sales based picture looks different. At a P/S of 2.5x versus peers at 4.8x and a fair ratio of 3.7x, the stock sits at a clear discount on revenue, so which signal do you trust more? To see how this sales based view stacks up against peers in more detail, take a closer look at the valuation breakdown, starting with the See what the numbers say about this price — find out in our valuation breakdown. NasdaqGS:BRKR P/S Ratio as at Jun 2026Next Steps If this Bruker story appears finely balanced between opportunity and risk, take a moment now to review the full picture for yourself with 3 key rewards and 1 important warning sign Looking for more investment ideas beyond Bruker? Once you have a view on Bruker, do not stop there. Broaden your watchlist with fresh ideas that match different investing goals and risk levels.  Target potential mispricings by scanning 44 high quality undervalued stocks that combine quality fundamentals with appealing price tags. Strengthen your income stream by reviewing 7 dividend fortresses built around higher yield opportunities. Prioritize resilience by checking 66 resilient stocks with low risk scores that score well on financial robustness and volatility.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Bruker might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2645400269","isCrawlerRequest":true}